Emcure Pharmaceuticals Q1 FY27: Revenue up 23% to ₹25,804 Mn, PAT rises 36% to ₹2,925 Mn
Emcure Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹25,804 Mn, up 22.8% YoY. PAT increased by 36.2% to ₹2,925 Mn. The company appointed Mr. Satish Mehta as Chairman and Mr. Samit Mehta as COO. Emcure also completed the acquisition of Gennova Biopharmaceuticals, making it a wholly owned subsidiary.
The substantial revenue and profit growth, coupled with strategic appointments and acquisitions, are likely to have a significant positive impact on investor sentiment and the company's market position.
The company reported significant year-on-year growth in revenue and profit, along with margin expansion, indicating strong operational performance. Key management changes and strategic acquisitions further contribute to a positive outlook.
Emcure Pharmaceuticals Limited announced its consolidated financial results for the first quarter ended June 30, 2026, reporting a strong start to FY27. The company's revenue from operations grew by 22.8% year-on-year to ₹25,804 million (Mn). EBITDA increased by 25.8% to ₹5,080 Mn, with the EBITDA margin improving to 19.7%, up approximately 50 basis points year-on-year, attributed to productivity gains and operating leverage. Profit After Tax (PAT) saw a significant rise of 36.2% to ₹2,925 Mn, with the PAT margin improving to 11.3%, up approximately 110 basis points year-on-year.
The domestic business contributed ₹10,953 Mn, showing a growth of 10.2%, driven by leading brands in CNS, cardiology, and women's health. The international business performed robustly, growing by 34.2% to ₹14,851 Mn, with Europe, Canada, and the Rest of the World regions all showing strong growth.
In terms of organizational and board changes, Mr. Berjis Desai will retire as Chairman of the Board of Directors at the conclusion of the forthcoming Annual General Meeting (AGM) due to his appointment to the National Commission for Minorities. Following the AGM, Mr. Satish Mehta will assume the role of Chairman, in addition to his current responsibilities as Managing Director and CEO. Mr. Samit Mehta has been appointed as the Chief Operating Officer (COO) of the company.
Furthermore, Emcure completed the acquisition of the minority stake in Gennova Biopharmaceuticals, making it a wholly owned subsidiary, and Mr. Samit Mehta has also been appointed as the CEO of Gennova. In R&D, Emcure licensed SHetA2, an anti-HPV candidate, and signed a licensing agreement with MSD for a generic version of its experimental oral HIV pill.
What to do with a filing like this
Emcure Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Emcure Pharmaceuticals Limited. Read the original for the full detail.